ATE503469T1 - Nanoteilchen zur abgabe von nukleinsäure - Google Patents

Nanoteilchen zur abgabe von nukleinsäure

Info

Publication number
ATE503469T1
ATE503469T1 AT07764504T AT07764504T ATE503469T1 AT E503469 T1 ATE503469 T1 AT E503469T1 AT 07764504 T AT07764504 T AT 07764504T AT 07764504 T AT07764504 T AT 07764504T AT E503469 T1 ATE503469 T1 AT E503469T1
Authority
AT
Austria
Prior art keywords
nanoparticles
release
nucleic acid
chitosan
rna
Prior art date
Application number
AT07764504T
Other languages
English (en)
Inventor
Flemming Besenbacher
Kenneth Alan Howard
Jorgen Kjems
Xiudong Liu
Original Assignee
Univ Aarhus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aarhus filed Critical Univ Aarhus
Application granted granted Critical
Publication of ATE503469T1 publication Critical patent/ATE503469T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07764504T 2006-07-07 2007-07-06 Nanoteilchen zur abgabe von nukleinsäure ATE503469T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81920906P 2006-07-07 2006-07-07
PCT/DK2007/050084 WO2008003329A2 (en) 2006-07-07 2007-07-06 Nanoparticles for nucleic acid delivery

Publications (1)

Publication Number Publication Date
ATE503469T1 true ATE503469T1 (de) 2011-04-15

Family

ID=38754461

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07764504T ATE503469T1 (de) 2006-07-07 2007-07-06 Nanoteilchen zur abgabe von nukleinsäure

Country Status (8)

Country Link
US (1) US20100015232A1 (de)
EP (3) EP2397123A1 (de)
AT (1) ATE503469T1 (de)
CA (1) CA2706124A1 (de)
DE (1) DE602007013559D1 (de)
DK (1) DK2037899T3 (de)
ES (1) ES2362376T3 (de)
WO (1) WO2008003329A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031899A2 (en) * 2006-09-15 2008-03-20 Fmc Biopolymer As Oligonucleotide non-viral delivery systems
WO2009048958A2 (en) * 2007-10-08 2009-04-16 The Board Of Regents Of The University Of Texas System Methods and compositions involving chitosan nanoparticles
AU2010306940A1 (en) 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
FR2963351B1 (fr) * 2010-07-30 2013-03-08 Univ Claude Bernard Lyon Particules formees d'un complexe polyelectrolyte de chitosane et d'un polysaccharide anionique, presentant une stabilite amelioree
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (de) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Manipulierte Nukleinsäuren und Verfahren zur Verwendung davon
WO2012094574A2 (en) * 2011-01-06 2012-07-12 The Johns Hopkins University Stabilized polyribonucleotide nanoparticles
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20140017330A1 (en) * 2011-04-04 2014-01-16 Board Of Regents Of The University Of Nebraska Activated Nucleoside Analog Conjugates and Methods of Use Thereof
AU2012260399A1 (en) 2011-05-24 2014-01-16 Polyvalor S.E.C. Compositions and methods for efficacious and safe delivery of siRNA using specific chitosan-based nanocomplexes
US8841272B2 (en) * 2011-05-31 2014-09-23 Kansas State University Research Foundation Double-stranded RNA-based nanoparticles for insect gene silencing
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013312749B2 (en) 2012-09-05 2018-01-18 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
US9801953B2 (en) 2012-10-15 2017-10-31 Emory University Nanoparticles carrying nucleic acid cassettes for expressing RNA
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
EP2971033B8 (de) 2013-03-15 2019-07-10 ModernaTX, Inc. Herstellungsverfahren zur herstellung von rna-transkripten
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
EP4279610A3 (de) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonukleinsäurereinigung
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
PL3019619T3 (pl) 2013-07-11 2022-01-10 Modernatx, Inc. Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (de) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynukleotidmoleküle und verwendungen davon
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
EP3151856B1 (de) * 2014-06-06 2019-08-07 Merck Patent GmbH Antigen-beladene chitosan-nanopartikel zur immuntherapie
AU2015289656A1 (en) 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
US9724307B2 (en) 2015-02-24 2017-08-08 San Heh Pharmaceutical Corporation Crosslinked nanoparticle composition
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
EP4101930A1 (de) 2015-09-17 2022-12-14 ModernaTX, Inc. Polynukleotide mit stabilisierendem schwanzbereich
BR112018071997A2 (pt) * 2016-04-26 2019-02-12 Viaqua Therapeutics Ltd nanopartícula de quitosana-rna, nanopartícula de quitosana-dsrna, composição nutracêutica, crustáceo criado em cativeiro, e método de tratamento ou prevenção de uma doença ou condição em um crustáceo criado em cativeiro associado a um vírus patogênico
US12385034B2 (en) 2016-06-24 2025-08-12 Modernatx, Inc. Methods and apparatus for filtration
JP7129912B2 (ja) * 2016-12-07 2022-09-02 株式会社ステリック再生医科学研究所 慢性疾患の治療及び予防用医薬組成物
US20210315214A1 (en) 2018-07-03 2021-10-14 Inl - International Iberian Nanotechnology Laboratory Pesticide
CN110396524B (zh) * 2019-05-31 2023-05-02 海南大学 一种用于蚊虫的RNAi纳米颗粒和制备方法及用途
KR102604882B1 (ko) * 2021-07-01 2023-11-21 인천대학교 산학협력단 신규 특이적 항암 및 항염증 siRNA 및 이의 용도
CN118679256A (zh) 2021-11-09 2024-09-20 微而广治疗有限公司 用于水产养殖的组合物
IT202100032393A1 (it) 2021-12-23 2023-06-23 Torino Politecnico Metodo per la preparazione di nanoparticelle polimeriche ibride per il rilascio di farmaci oligonucleotidici nelle terapie farmacologiche a scopo rigenerativo, curativo e preventivo
CN115992131A (zh) * 2022-07-22 2023-04-21 江苏省农业科学院 一种纳米化壳聚糖/dsGRK复合体及其制备方法和应用
JP2026508358A (ja) 2023-03-02 2026-03-10 クリスタル バイオテック インコーポレイテッド がん治療用のインターロイキン－２およびインターロイキン－１２
CN118304423B (zh) * 2023-05-25 2024-10-11 无锡市第二人民医院 多层级壳聚糖明胶颗粒载P4HA1 siRNA通过抑制细胞EMT治疗脑胶质瘤的研究

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
NO317653B1 (no) * 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som omfatter komplekser av kitosanoligomerer og nukleinsyre, fremgangsmate for a fremstille formuleringen samt anvendelser derav.
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
EP1658304A4 (de) * 2002-09-28 2009-01-14 Massachusetts Inst Technology Mittel zur behandlung von grippe
US20040138154A1 (en) * 2003-01-13 2004-07-15 Lei Yu Solid surface for biomolecule delivery and high-throughput assay
US20050013854A1 (en) * 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
WO2005113770A1 (en) * 2004-05-13 2005-12-01 Institut Gustave Roussy Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them.
WO2008031899A2 (en) * 2006-09-15 2008-03-20 Fmc Biopolymer As Oligonucleotide non-viral delivery systems

Also Published As

Publication number Publication date
EP2295045A1 (de) 2011-03-16
WO2008003329A2 (en) 2008-01-10
DK2037899T3 (da) 2011-05-09
EP2037899B1 (de) 2011-03-30
ES2362376T3 (es) 2011-07-04
EP2397123A1 (de) 2011-12-21
DE602007013559D1 (de) 2011-05-12
CA2706124A1 (en) 2008-01-10
WO2008003329A3 (en) 2008-02-21
US20100015232A1 (en) 2010-01-21
EP2037899A2 (de) 2009-03-25

Similar Documents

Publication Publication Date Title
DE602007013559D1 (de) Nanoteilchen zur abgabe von nukleinsäure
ES3065530T3 (en) Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
WO2008151022A3 (en) Nucleic acid nanoparticles and uses therefor
BRPI0818374A8 (pt) Substratos porosos hidrofílicos
WO2010026488A3 (en) Methods and kits for nucleic acid sequencing
EP4279610A3 (de) Ribonukleinsäurereinigung
EP2032714A4 (de) Chemisch modifizierte oligonukleotidprimer zur nukleinsäureamplifikation
WO2013165816A3 (en) SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2013143700A3 (en) Artificial nucleic acid molecules comprising a 5'top utr
WO2006110688A3 (en) Rnai therapeutic for respiratory virus infection
WO2008134761A3 (en) Modification of biological targeting groups for the treatment of cancer
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
WO2009074970A3 (en) Means for delivery of nucleic acids active for gene silencing using synthetic polymers
WO2009108217A3 (en) Compositions comprising k-ras sirna and methods of use
WO2009114475A3 (en) Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
BRPI0811755A2 (pt) Amplificação específica de senquência de dna específicas de tumor.
DE502007006037D1 (de) Multimer zur immunstimulation
EP2647711A3 (de) Alternative Exportwege für über einen Vektor exprimierte RNA-Interferenz
WO2012093833A3 (en) Genome engineering via designed tal effector nucleases
WO2010003420A3 (en) Treatment of psoriasis and related diseases by mirna modulation
WO2012177695A3 (en) Hybrid polymerases having the ability to produce long amplicons
GB0917615D0 (en) Method for increasing the speed of nucleic acid amplification reactions
WO2012170907A3 (en) Polymerization of nucleic acids using proteins having low isoelectric points
WO2009143277A3 (en) Compositions comprising hscn9a sirna and methods of use thereof
WO2009071680A3 (en) Rna antagonist compounds for the modulation of mcl-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties